Imunon, Inc. · NASDAQ:IMNN
Imunon — MedInvest Biotech and Pharma Investor Conference (April 2026)
16 slides from Imunon's conference presentation, Apr 1, 2026
Slide 1: MedInvest Biotech and Pharma Investor Conference
Developing medicines harnessing the capability of DNA to power body’s MedInvest Biotech and immune system Pharma Investor Conference April 1, 2026 © 2024 IMUNON, Inc. Nasdaq: IMNN PAGE 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Imunon, Inc. (“IMUNON” or the “Company”) or any person on their behalf, any question-and-a
Slide 3: Product Pipeline of DNA-based Transformative Medicines
Product Pipeline of DNA-based Transformative Medicines Platform Delivery Program Indication(s) Discovery IND Phase 1 Phase 2 Phase 3 enabling Partner Newly Diagnosed Adv. IL-12 (OVATION 2) Ovarian Cancer IMNN-001 Q1’26 completed Newly Diagnosed Adv. IL-12 (OVATION 3) Ovarian Cancer IMNN-001 enrollin
Slide 4: Great Unmet Need: Patient Outcomes and Frontline Standard of Care Unchanged for 30 years
Great Unmet Need: Patient Outcomes and Frontline Standard of Care Unchanged for 30 years Recurrence Rates are High and Survival Rates are Low Epithelial ovarian cancer (EOC) is insidious and usually diagnosed at an advanced stage. Though EOC initially responds to treatment, the recurrence rate is hi
Slide 5: IMNN-001: A Potential Breakthrough in Newly Diagnosed Ovarian Cancer
IMNN-001: A Potential Breakthrough in Newly Diagnosed Ovarian Cancer No other frontline ovarian cancer trial has shown an OS improvement; IMNN-001 has a highly favorable benefit/risk profile IMNN-001 may be the 1st immuno-therapy for ovarian cancer, with the potential to transform the standard of ca
Slide 6: K-M Plot of Overall Survival, ITT population, OVATION-2 final analysis
K-M Plot of Overall Survival, ITT population, OVATION-2 final analysis July 2024 ∆medians 11.1 months → Final Analysis: ∆medians 14.7 months Median OS: 45.1 mo IMNN+NACT, 30.4 mo NACT Difference, 95% CI: 14.8 (-3.8, 33.3), one-sided p-value = 0.056 Modified Weighted Log Rank, one-sided p-value = 0.0
Slide 7: K-M Plot of Overall Survival, PARPi treated pts, OVATION-2 final analysis
K-M Plot of Overall Survival, PARPi treated pts, OVATION-2 final analysis July 2024 ∆medians not evaluable → Final Analysis: ∆medians 24.2 months Median OS: 65.6 mo IMNN+NACT, 41.4 mo NACT, Difference 24.2 mo* Modified Weighted Log Rank, one-sided p-value = 0.186 © 2024 IMUNON, Inc. *Due to the smal
Slide 8: Our Phase 2 Clinical Research is of Great Importance to the Medical Community
8 Our Phase 3 Clinical Research is of Great Importance to the Medical Community • Our Landmark Phase 2 Study was Showcased at ASCO with a Platform Presentation • Published in Gynecologic Oncology, Premier Medical Outlets © 2024 IMUNON, Inc. PAGE 8
Slide 9: OVATION 2 Treatment Effect Consistently Favors IMNN-001 Across All Trial Endpoints and Pre-specified Subgroups
OVATION 2 Treatment Effect Consistently Favors IMNN-001 Across All Trial Endpoints and Pre-specified Subgroups Consistent treatment effect in ongoing Phase 2 MRD Trial*: • Lower MRD-positivity rate • Lower % of positive biopsies • Higher Progression Free Survival • Higher CRS at cytoreduction *MRD:
Slide 10: OVATION 3: Purposeful Protocol Design & Rigorous Methodology
OVATION 3: Purposeful Protocol Design & Rigorous Methodology Frontline Therapy Maintenance Therapy Laparoscopy NACT (3 cycles) + ACT (3 cycles) + PARPi treatment: HRD Interval Debulking Surgery IMNN-001 (weekly) IMNN-0 0 1 (weekly) participants only 500 (or 250 HRD) Stage IIIB/C or IV EOT visit EOC
Slide 11: IMUNON in Phase 3, Well Positioned with Early Stopping Potential
IMUNON in Phase 3, Well Positioned with Early Stopping Potential Executing against the plan as promised… • Robust Data from 112 patient OVATION-2 (Phase 2) demonstrating IMNN-001 improvement over SoC • Confidence in Phase 3 trial based on consistency of clinical data across all endpoints and subgrou
Slide 12: IMNN-001 Targets the Micro-Environment of Ovarian Cancer
IMNN-001 Targets the Micro-Environment of Ovarian Cancer Local production of safe and durable levels of a powerful anti-cancer immune agent, IL-12 Safe administration weekly, demonstrated over a 6-month period Local Expression of IL-12 Favors Immune Modulation in Tumor Interleukin 12 Induces Strong
Slide 13: IMNN-001 Has a Broad Impact, Fundamentally Alters Tumor Microenvironment
IMNN-001 Has a Broad Impact, Fundamentally Alters Tumor Microenvironment Translational Data Sampling Confirms 100 mg/m2 as the Phase 3 dose IMNN-001 dose-dependent and local selective expression of IL-12 and IFN-γ levels in patients’ samples OVATION-1 OVATION-2 Increases in cytokine levels at tumo
Slide 14: IMNN-001 has a Highly Favorable Benefit/Risk Profile Through Phase 2
IMNN-001 has a Highly Favorable Benefit/Risk Profile Through Phase 2 OVATION 2 Phase 2 Key safety observations: • No systemic dose limiting toxicities associated with IV administration of IL-12 were observed • Cytokine release syndrome (CRS) did not occur with IMNN-001 treatment • No elevation of im
Slide 15: Investment Thesis
Investment Thesis Funding IMNN-001 IL-12 Registrational Study for 1st line Ovarian Cancer • Unprecedented data in a randomized, well controlled Phase 2 with compelling OS efficacy in newly diagnosed OV population • Data driven Registrational study design based on strong evidence, leveraging establis
Slide 16: Corporate Information
Corporate Information Headquarters Research Facility Princeton, NJ Huntsville, AL IMUNON P: 609-896-9100 997 Lenox Drive F: 609-896-2200 Suite 100 Lawrenceville, NJ 08648 www.imunon.com Nasdaq: IMNN © 2024 IMUNON, Inc. PAGE 16
Imunon — MedInvest Biotech and Pharma Investor Conference (April 2026) on 6ix